New combo therapy shows promise in tough liver cancer cases
NCT ID NCT06354387
First seen Mar 30, 2026 · Last updated Apr 28, 2026 · Updated 3 times
Summary
This pilot study tested a combination of two drugs, alectinib and nivolumab, in 5 adults with recurrent or hard-to-treat liver cancer. The goal was to see if the combination could shrink tumors or slow cancer growth. Participants had already tried standard treatments without success. The study measured how many patients responded and how long they lived without the cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CMUH
Taichung, Taiwan
Conditions
Explore the condition pages connected to this study.